Mednet Logo
HomeDermatology
Dermatology

Dermatology

Clinical insights on skin conditions, dermatologic procedures, and treatment approaches from practicing dermatologists.

Recent Discussions

Do certain subtypes of BCC respond better to hedgehog pathway inhibitors?

1 Answers

Mednet Member
Mednet Member
Dermatology · Geisinger Commonwealth Medical College

I have found that the larger the BCC, the more dramatic the response (unfortunately, not all tumors respond). These are invariably of the nodular/infiltrative subtypes for which hedgehog inhibitors are indicated.

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Mayo Clinic College of Medicine

Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...

What is your strategy for managing radiation dermatitis in breast cancer in the prophylactic, erythema/dry desquamation, and moist desquamation stages?

12
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Good question. Everyone seems to have a favorite home remedy with very little good supporting data. I am unaware of any good prophylaxis rx. The best thing is good treatment planning to minimize inhomogeneity. There are phase III data demonstrating the efficacy of soap and water cleansing for rx of ...

How do you approach selection of systemic treatment in a patient with atopic dermatitis with severe itch?

1 Answers

Mednet Member
Mednet Member
Dermatology · UCONN

The good news is we have 6 approved options here, 4 biologics and 2 small molecules, and all of these therapies have excellent itch data. Selecting a systemic therapy needs to take other comorbid conditions, medications, delivery preference (pill or injection), lifestyle, and other patient attribute...

Do you prefer switching to a biologic with a different mechanism of action such as an IL-17 inhibitor over cycling to another TNF inhibitor in a patient with moderate-to-severe HS who has experienced secondary failure to adalimumab after an initial good response?

2 Answers

Mednet Member
Mednet Member
Dermatology · Wayne State University

I agree with @Dr. First Last's excellent suggestions. One other idea is adding methotrexate 10 mg weekly to adalimumab to see if neutralizing antibodies are the problem. I tend to do this if a patient has a good response but loses it down the road. I don't do this as much as I used to, now that we h...

With the increasing availability of biosimilars and their adoption onto payer formularies, how do you approach selection among available biosimilars in clinical practice?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · Texas Christian University

Insurance payers consider FDA‑approved biosimilars to be clinically equivalent. In my experience, selection is ultimately driven by the insurance payer formulary - what you can get for the patient on the time. This can be fleeting and quickly changing at times. Cases can be made for patient experien...

How do you approach managing perioperative anxiety in Mohs patients?

1 Answers

Mednet Member
Mednet Member
Dermatology · University of Iowa

Great question. Music, stress balls, having your team engage in conversations with the patient, and other distraction techniques are helpful. Some patients may need medications such as Halcion to help with anxiety but this should be given after the patient signs consent and has a verified driver aft...

How do you clinically and diagnostically distinguish stiff skin syndrome from scleroderma?

1
3 Answers

Mednet Member
Mednet Member
Rheumatology · Arthritis Associates

One other disease consideration that one should differentiate is diabetic cheiroarthropathy, or "diabetic stiff hand syndrome." These patients can see decreased extension of the digits (often referred to as "Prayer sign" changes) and thickening of the skin in the digits. This can be present in 50% o...

How do you decide when to recommend non-surgical management of Bowen's disease in light of long-term data showing very low risk of invasive cSCC after treatment with 5-FU as compared to surgical excision?

1
2 Answers

Mednet Member
Mednet Member
Dermatology · University of Washington School of Medicine

Generally, this is a low-risk lesion that can be treated effectively by a variety of modalities or, in some cases, not treated. However, one should always bear in mind that a biopsy may not truly represent the full extent of the lesion. One of the worst invasive SCCs I’ve observed was initially read...

Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?

4
1 Answers

Mednet Member
Mednet Member
Dermatology · Johns Hopkins Timeshare Practice

Can certainly help when patients have conditions that trigger Raynaud's. If otherwise healthy, I discuss keeping the extremities protected from excessive cooling.